Oncorus’s armed oHSV selectively infects and replicates in tumor cells, eventually causing tumor cell lysis. Upon lysis, multiple “personalized” tumor antigens and therapeutic immune modulatory payloads are released into the local environment. Neoantigens and immune payloads stimulate and recruit immune cells to destroy local and distant tumors, resulting in a highly effective cancer therapeutic treatment.
Oncorus is developing potent oncolytic immunotherapies for malignant and benign tumors.
Robust Viral Potency
Critical γ34.5 gene retained to maintain wild type replication & inhibit IDO activity
Proprietary glycoprotein modifications to enhance target cell entry.
Multiple Immune-Modulatory Payloads
Large 25kb capacity enables integration of multiple payloads capable of recruiting all arms of the immune system.
Tumor Matrix Modification
Matrix metalloproteinases degrade the extracellular matrix and facilitate viral spread, enhancing efficacy.
miR Controlled Replication & Payload Expression
Engineering of miR-T cassettes into critical replication genes allows robust replication in tumor tissues; arming genes expressed in tumor only, increasing potency & limiting toxicity.
Targeted Viral Entry
Retargeted glycoproteins enables selective uptake by cells expressing tumor antigens.
Armed oHSV Vector
Robust anti-tumor effect following direct injection of unarmed Oncorus oHSV
Even greater tumor regression with armed Oncorus oHSV
Modest abscopal response observed with unarmed oHSV
Robust abscopal effect observed in non-injected tumor with single immune payload
A20 flank tumor model demonstrates that armed oHSV induces robust oncolysis in injected tumor (top panel) and potent abscopal response in uninjected tumor (lower panel).